Neurosom is a neurotechnology company that has developed a personalized, at-home neuromodulation therapy to improve deep (N3) and REM sleep, processes that support brain maintenance, cognitive resilience, and healthy aging. Neurosom’s initial clinical focus is dementia risk reduction, leveraging personalized neuromodulation to support glymphatic clearance in older adults, with first studies centered on mild cognitive impairment (MCI).

Its lead product, Sleep WISP™, is a wearable, EEG-guided, closed-loop stimulation system currently under evaluation in NIH/NIA-funded, multi-center MCI studies, with a roadmap toward regulated clinical and scalable brain health applications.

Neurosom was founded by a team of pioneers in HD EEG and personalized, non-invasive electrical neuromodulation, with a prior successful exit to Philips. The platform integrates FDA-cleared AI sleep-staging and brain modeling software, and HD EEG–based clinical assessment, linking precision diagnosis to home therapy.